Paul De Vos

Dr. Paul De Vos

Pathology and Medical Biology, section Immunoendocrinology, University Medical Center Groningen (UMCG), Hanzeplein 1, EA 149713 GZ Groningen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in International Dairy Journal
Verified
Journal Article
Closed access
Paul De VosPaul De Vos
Paul De Vos
MFMarijke M. Faas
Marijke M. Faas
MSMilica Spasojevic
Milica Spasojevic
JSJan Sikkema
Jan Sikkema

26 May 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
NGNaschla Gasaly
Naschla Gasaly
Paul De VosPaul De Vos
Paul De Vos
MHMarcela Hermoso
Marcela Hermoso
The diverse and dynamic microbial community of the human gastrointestinal tract plays a vital role in health, with gut microbiota supporting the development and function of the gut immune barrier. Crosstalk between microbiota-gut epithelium and the gut immune system determine the individual health status, and any crosstalk disturbance may lead to chronic intestinal conditions, such as inflammatory bowel diseases (IBD) and celiac disease. Microbiota-derived metabolites are crucial mediators of host-microbial interactions. Some beneficially affect host physiology such as short-chain fatty acids (SCFAs) and secondary bile acids. Also, tryptophan catabolites determine immune responses, such as through binding to the aryl hydrocarbon receptor (AhR). AhR is abundantly present at mucosal surfaces and when activated enhances intestinal epithelial barrier function as well as regulatory immune responses. Exogenous diet-derived indoles (tryptophan) are a major source of endogenous AhR ligand precursors and together with SCFAs and secondary bile acids regulate inflammation by lowering stress in epithelium and gut immunity, and in IBD, AhR expression is downregulated together with tryptophan metabolites. Here, we present an overview of host microbiota-epithelium- gut immunity crosstalk and review how microbial-derived metabolites contribute to host immune homeostasis. Also, we discuss the therapeutic potential of bacterial catabolites for IBD and celiac disease and how essential dietary components such as dietary fibers and bacterial tryptophan catabolites may contribute to intestinal and systemic homeostasis.

1 August 2000 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
HUHasan Uludag
Hasan Uludag
Paul De VosPaul De Vos
Paul De Vos
PTPatrick A Tresco
Patrick A Tresco

1 January 2003 in Nature Medicine
Verified
Journal Article
Closed access
GOGorka Orive
Gorka Orive
Rosa Maria HernandezRosa Maria Hernandez
Rosa Maria Hernandez
Alicia Rodríguez-GascónAlicia Rodríguez-Gascón
Alicia Rodríguez-Gascón
RCRiccardo Calafiore
Riccardo Calafiore
TCThomas M.S. Chang
Thomas M.S. Chang
José Luis PedrazJosé Luis Pedraz
José Luis Pedraz

1 November 2006 in Biomaterials
Verified
Journal Article
Closed access
Paul De VosPaul De Vos
Paul De Vos
MFMarijke M. Faas
Marijke M. Faas
BSBerit Strand
Berit Strand
RCRicardo Calafiore
Ricardo Calafiore

1 November 2010 in Current Opinion in Clinical Nutrition and Metabolic Care
Verified
Journal Article
Closed access
KMKees Meijer
Kees Meijer
Paul De VosPaul De Vos
Paul De Vos
MPMarion G Priebe
Marion G Priebe
High-fiber diets have been shown to reduce plasma concentrations of inflammation markers. Increased production of fermentation-derived short-chain fatty acids (SCFAs) is one of the factors that could exert these positive effects. This review examines the effects of SCFAs on immune cells and discusses the relevance of their effects on systemic inflammation, as frequently seen in obesity. SCFAs have been shown to reduce chemotaxis and cell adhesion; this effect is dependent on type and concentration of SCFA. In spite of conflicting results, especially butyrate seems to have an anti-inflammatory effect, mediated by signaling pathways like nuclear factor-κB and inhibition of histone deacetylase. The discrepancies in the results could be explained by differences in cell types used and their proliferative and differentiation status. SCFAs show anti-inflammatory effects and seem to have the potency to prevent infiltration of immune cells from the bloodstream in, for example, the adipose tissue. In addition, their ability to inhibit the proliferation and activation of T cells and to prevent adhesion of antigen-presenting cells could be important as it recently has been shown that obesity-associated inflammation might be antigen-dependent. More studies with concentrations in micromolar range are needed to approach more physiological concentrations.